Latest Conference Articles

Read on to see which data are poised to shape clinical discussions and decision-making in lung cancer at the 2026 ESMO Congress in Madrid, Spain.

Jesús Berdeja, MD, discusses how CELMoDs such as iberdomide and mezigdomide may reshape standard-of-care treatment in multiple myeloma.

Experts in gynecologic oncology overview top research being presented at the 2026 ESMO Congress.

First-line IO-based combination regimens were increasingly used and associated with longer observed survival in advanced renal cell carcinoma.

Readers share their opinions on some of the most talked-about breast cancer abstracts they’re looking forward to seeing at ESMO 2026.

Experts spotlight the gastrointestinal cancer presentations they’re most excited to see at the 2026 ESMO Congress.

Experts break down key lung cancer data and trends from the IASLC 2026 World Conference on Lung Cancer.

Young Kwang Chae, MD, discusses tumor-informed and tissue-agnostic ctDNA MRD assays in postsurgical lung cancer surveillance.

Experts break down key multiple myeloma data and trends from the 23rd Annual IMS Meeting.

Binod Dhakal, MD, MS, discusses allogeneic and in vivo CAR T-cell therapies under investigation in relapsed/refractory multiple myeloma.

Mary Ann Anderson, MBBS, FRACP, FRCPA, PhD, discusses unresolved treatment choices in chronic lymphocytic leukemia.

Experts spotlight the variety of breast cancer research being presented at the 2026 ESMO Congress.

The first MRD data from the phase 3 EXCALIBER-RRMM trial support iberdomide-based triplet therapy as early as first relapse, with PFS follow-up ongoing.

After nearly 7 years of follow-up, daratumumab added to VRd continued to improve PFS, PFS2, and sustained MRD negativity in transplant-eligible myeloma.

Peter Voorhees, MD, discusses CRS and infection data for etentamig from the phase 3 CERVINO trial in triple-class–exposed relapsed/refractory myeloma.

Peter Voorhees, MD, discusses phase 3 CERVINO data for etentamig vs standard therapies and next steps for the agent in relapsed/refractory myeloma.

Sagar Lonial, MD, FACP, FASCO, discusses MRD-negativity data with iberdomide plus daratumumab and dexamethasone in relapsed/refractory multiple myeloma.

Sagar Lonial, MD, FACP, FASCO, discusses Project Optimus dose selection and MRD as an early end point in the phase 3 EXCALIBER-RRMM trial.

Monthly etentamig significantly improved response and PFS over standard available therapies in the phase 3 CERVINO trial, with low rates of high-grade CRS.

Dirk van Esser, MD, discusses safety with KRd in the EMN15/HOVON147 trial and how to select patients with high-risk smoldering myeloma for treatment.

Dirk van Esser, MD, discusses long-term EMN15/HOVON147 data for KRd vs Rd in high-risk smoldering multiple myeloma.

Jessica Encinas Mayoral, PhD, discusses preclinical data on an AI-designed BCMA/FcRL5 trispecific antibody in multiple myeloma.

Jessica Encinas Mayoral, PhD, discusses the design and antigen-independent activity of a BCMA/FcRL5 trispecific antibody in multiple myeloma.

Extended follow-up from the phase 1b CAMMA 1 trial showed durable responses across 2 cevostamab dose levels, supporting selection of a recommended phase 3 regimen.

A MAIC found anito-cel produced response rates similar to those of cilta-cel, with fewer high-grade toxicities, in relapsed/refractory multiple myeloma.

Updated phase 2 LINKER-SMM1 data show single-agent, fixed-duration linvoseltamab produced deep, durable, and MRD-negative responses in high-risk smoldering multiple myeloma.

Ja Min Byun, MD, PhD, discusses response consistency and the future of mezigdomide plus elranatamab in multiple myeloma.

Ja Min Byun, MD, PhD, discusses updated phase 1 findings with mezigdomide plus elranatamab in relapsed/refractory multiple myeloma.

Mary Ann Anderson, MBBS, FRACP, FRCPA, PhD, explains how safety, resistance, and sequencing guide frontline therapy selection in CLL.

Brad S. Kahl, MD, discusses how the TRIANGLE trial supports frontline therapy without autologous transplantation in mantle cell lymphoma.